Vecuronium
Nondepolarizing Neuromuscular Blocker — MUSCULO-SKELETAL SYSTEM
Also known as: Org NC 45, vecuronium bromide, vecuronium citrate, vecuronium HCl, vecuronium hydrobromide, vecuronium hydrochloride, vecuronium maleate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Vecuronium is an ofp drug in the Nondepolarizing Neuromuscular Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1984. DrugCentral lists 13 molecular targets, including CHRM1, CHRM4 and CHRM5. Recorded indications include General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
- Approval status: ofp (first approved 1984 by the FDA).
- Drug class: Nondepolarizing Neuromuscular Blocker.
- Molecular targets: CHRM1, CHRM4, CHRM5 and CHRM3 (13 listed in DrugCentral).
- Indications: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
- ATC code: M03AC03 (Other quaternary ammonium compounds).
- Molecular formula: C34H57N2O4; molecular weight 557.84 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- General anesthesia
- Muscle relaxation, function
- Skeletal Muscle Relaxation for Endotracheal Intubation
Contraindications (7)
- Cirrhosis of liver
- Disorder of electrolytes
- Eaton-Lambert syndrome
- Morbid obesity
- Myasthenia gravis
- Neuromyopathy
- Obstruction of bile duct
Mechanism & targets
| Established pharmacologic class | Nondepolarizing Neuromuscular Blocker |
|---|
Molecular targets (13)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | CHRM1 | unknown | IC50 9.90 |
| Muscarinic acetylcholine receptor M4 | CHRM4 | unknown | IC50 9.80 |
| Muscarinic acetylcholine receptor M5 | CHRM5 | unknown | IC50 9.70 |
| Muscarinic acetylcholine receptor M3 | CHRM3 | unknown | IC50 9.60 |
| Muscarinic acetylcholine receptor M2 | CHRM2 | unknown | IC50 9.30 |
| Acetylcholine receptor | CHRNA1|CHRNB1|CHRND | antagonist | IC50 7.82 |
| Acetylcholine receptor; alpha1/beta1/delta/gamma | CHRNA1|CHRNG|CHRNB1|CHRND | unknown | IC50 7.09 |
| Multidrug and toxin extrusion protein 1 | SLC47A1 | unknown | IC50 5.72 |
| Solute carrier family 22 member 2 | SLC22A2 | unknown | IC50 5.46 |
| Multidrug and toxin extrusion protein 2 | SLC47A2 | unknown | IC50 4.60 |
| Neuronal acetylcholine receptor; alpha4/beta2 | CHRNB2|CHRNA4 | unknown | — |
| Neuronal acetylcholine receptor; alpha4/beta4 | CHRNB4|CHRNA4 | unknown | — |
| Neuronal acetylcholine receptor; alpha2/beta4 | CHRNB4|CHRNA2 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1984-04-30 | FDA | — | ORGANON USA INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M03AC03 | MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Hyperthermia malignant | 256.2 |
| Anaphylactic reaction | 251.9 |
| Cardiac arrest | 221.3 |
| Neuromuscular block prolonged | 183.3 |
| Hypotension | 177.4 |
| Bradycardia | 175.7 |
| Delayed recovery from anaesthesia | 111.5 |
| Anaphylactic shock | 104.5 |
| Drug interaction | 101.6 |
| Fear | 99.3 |
| Post procedural complication | 99.3 |
| Feeding intolerance | 93.2 |
Chemical structure
| Molecular formula | C34H57N2O4 |
|---|---|
| Molecular weight | 557.84 g/mol |
| CAS number | 50700-72-6 |
| InChIKey | BGSZAXLLHYERSY-XQIGCQGXSA-N |
| PubChem CID | 39765 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Vecuronium used for?
DrugCentral lists the following indications for Vecuronium: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
How does Vecuronium work?
Its molecular targets in DrugCentral include CHRM1, CHRM4, CHRM5 and CHRM3.
When was Vecuronium first approved?
Vecuronium was first approved by the FDA in 1984.
What drug class does Vecuronium belong to?
Vecuronium is in the Nondepolarizing Neuromuscular Blocker class.
What is the chemical formula of Vecuronium?
Vecuronium has the molecular formula C34H57N2O4 and a molecular weight of 557.84 g/mol.
Browse: all drugs starting with V · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2811 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200629 — compound record and bioactivity
- PubChem CID 39765 — chemical identifiers
- DrugBank DB01339 — drug record
- FDA UNII 5438723848 — substance identity
- DailyMed: FDA labels for Vecuronium — current prescribing information (label search)
- UniProt P11229 (CHRM1) — target protein
- UniProt P08173 (CHRM4) — target protein
- UniProt P08912 (CHRM5) — target protein
- UniProt P20309 (CHRM3) — target protein
- UniProt P08172 (CHRM2) — target protein
- UniProt Q96FL8 (SLC47A1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.